|
Meglutol
|
DB04377 |
[An antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids. It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethylglutaryl coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which is the rate limiting enzyme in the biosynthesis of cholesterol.] |
|
3-Deazacytidine
|
DB04385 |
|
|
Bromoform
|
DB03054 |
|
|
4,6-O-(1-Carboxyethylidene)-Beta-D-Glucose
|
DB04386 |
|
|
L-valinol
|
DB04383 |
|
|
Dazoxiben
|
DB03052 |
|
|
1-Aminocyclopropylphosphonate
|
DB03053 |
|
|
Fe-Mesopone
|
DB04384 |
|
|
Crotonaldehyde
|
DB04381 |
|
|
Tetrahydrofuran-2-Carboxylic Acid
|
DB03051 |
|
|
2-Deoxy-Beta-D-Galactose
|
DB04382 |
|
|
Allantoate
|
DB04380 |
|
|
ITI-214
|
DB15039 |
[ITI-214 is under investigation in clinical trial NCT03489772 (Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement).] |
|
Sitravatinib
|
DB15036 |
[Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).] |
|
Zanubrutinib
|
DB15035 |
[Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.[L10163] Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma that is associated with early relapse, poor clinical outcomes, and long-term survival.[A187967] BTK is an enzyme that plays a role in oncogenic signalling pathways, where it promotes the survival and proliferation of malignant B cells.[A187985] Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects.[A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017.
Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[L10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug.[L10169] It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules.] |
|
Litoxetine
|
DB15038 |
[Litoxetine is under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence).] |
|
Poly(lactic acid)
|
DB15037 |
[Poly(lactic acid) is under investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy).] |
|
Obexelimab
|
DB15032 |
[Obexelimab is under investigation in clinical trial NCT02725515 (A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus).] |
|
Nemorexant
|
DB15031 |
[Nemorexant is under investigation in clinical trial NCT03101189 (A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects).] |
|
PRI-724
|
DB15034 |
[PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).] |
